Robert Bartlett

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

Thomas Mattar, Kulvinder S. Kochhar, Robert Bartlett et al. · FEBS Letters · 1993 · 154 citations · Full text

Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity — I. Disease modifying action on adjuvant arthritis of the rat

Robert Bartlett, R. Schleyerbach · International Journal of Immunopharmacology · 1985 · 131 citations

Inflammation, Rheumatology, Rheumatoid Disorder +13

Immunopharmacological profile of HWA 486, a novel isoxazol derivative— II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A

Robert Bartlett · International Journal of Immunopharmacology · 1986 · 60 citations

Clinical Immunology, Immunopharmacological Profile, Medicine +7

Immunomodulation of proteoglycan-induced progressive polyarthritis by lefluflomide

Tibor T. Giant, Katalin Mikecz, Robert Bartlett et al. · Immunopharmacology · 1992 · 44 citations

Inflammation, Rheumatology, Rheumatoid Disorder +8

Leflunomide prevents the development of experimentally induced myasthenia gravis

Biljana Vidic-Dankovic, Duško Kosec, Maja Damjanović et al. · International Journal of Immunopharmacology · 1995 · 41 citations

Molecular Pharmacology, Anti-inflammatory, Molecular Physiology +7